Another hypothesis is that rapamycin and analogs can suppress the inflammation reaction by increasing IL-1β and other inflammatory cytokines and chemokines in the neocortex and hippocampus (Zhang et al., 2015) mTORC1 antagonists in the treatment of focal epilepsy are promising, especially for individuals carrying mutations of GATOR1 genes, including DEPDC5, NPRL2, and NPRL3. This evidence concerns the gene NPRL3 and focal epilepsy.